NATALIZUMAB IN MULTIPLE SCLEROSIS – A REVIEW OF DIFFERENT DOSING REGIMENS, SIDE EFFECTS, COMPARISON WITH OTHER DISEASE-MODIFYING THERAPIES WITH ADDITIONAL ATTENTION TO USE IN PREGNANCY AND THE PEDIATRIC POPULATION
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.5801Keywords:
Natalizumab, Multiple Sclerosis, Demyelination, Central Nervous System Pathology, Disease Mechanisms, Neurological Symptoms, Therapeutic Approaches, Pregnancy, Side EffectsAbstract
Objective: The aim of this review was to evaluate the clinical efficacy, optimization of dosing regimens, safety profile, and socioeconomic aspects of natalizumab (NTZ) use in the treatment of multiple sclerosis (MS), with a additional focus on pregnant and pediatric populations.
Methodology: A systematic review of the PubMed database was conducted, identifying 220 records. Thirty-two publications meeting the criteria regarding the mechanism of action, efficacy, adverse event profile, and comparison with other disease-modifying therapies (DMTs) were included in the final analysis.
Results: The analysis demonstrated that the extended interval dosing (EID, every 6 weeks) regimen maintains clinical and radiological efficacy comparable to the standard interval dosing (SID, every 4 weeks), while significantly reducing the risk of progressive multifocal leukoencephalopathy (PML) by 88–94%. It was recognized that natalizumab is safer than other DMTs, such as ocrelizumab, without compromising efficacy. In the pediatric population, NTZ showed the highest efficacy in reducing relapse rates compared to fingolimod and injectable therapies. In pregnant women, continuing treatment until the 34th week prevents postpartum rebound relapses and improves EDSS scores, showing no teratogenic effects. Economically, the subcutaneous form of NTZ and the use of EID generate significant direct and societal cost savings.
Conclusions: Natalizumab remains a highly effective and cost-efficient therapeutic option for the treatment of relapsing-remitting MS. Personalization of treatment through the EID regimen and the subcutaneous formulation allows for an improved safety profile and patient quality of life, while simultaneously reducing the systemic burden on healthcare.
References
Le Page, E., Emery, C., Fravalo, A., Fagnani, F., & Clement, A. (2025). Trends in the real-world management of patients with active relapsing-remitting multiple sclerosis treated with natalizumab (TYSABRIW) in France: An analysis of the PMSI database over five years (2019–2023). Revue Neurologique, 181, 535–543. https://doi.org/10.1016/j.neurol.2025.03.001
Monschein, T., Untersteiner, H., Ponleitner, M., Krajnc, N., Zrzavy, T., Bsteh, G., Rommer, P., Kornek, B., Enzinger, C., Di Pauli, F., Kraus, J., Guger, M., Leutmezer, F., Berger, T., & The Austrian MS Treatment Registry (AMSTR). (2025). Safety of disease modifying therapies in multiple sclerosis: Real world data from the Austrian MS Treatment Registry (AMSTR). Journal of Neurology, 272, 774. https://doi.org/10.1007/s00415-025-13473-7
El Mahdaoui, S., Kosa, P., Komori, M., Veiga González, J. L., Højsgaard Chow, H., Ratzer, R., Gøbel Madsen, C., Siebner, H. R., Bielekova, B., Villar, L. M., Christensen, J. R., & Sellebjerg, F. (2025). Profiling the cerebrospinal fluid proteome in progressive multiple sclerosis: Treatment effects and associations with IgM oligoclonal bands. Journal of Neuroimmune Pharmacology, 20, 98. https://doi.org/10.1007/s11481-025-10263-w
Hamnvik, L. H. D., Tjønnfjord, G. E., Spetalen, S., & Dalgaard, J. (2024). Long-lasting severe anemia following treatment with natalizumab for relapsing–remitting multiple sclerosis: A case report. Journal of Medical Case Reports, 18, 245. https://doi.org/10.1186/s13256-024-04562-8
Prosperini, L., Brescia Morra, V., Fornari, C., Santoni, L., Perini, D., Bergamaschi, R., & Cortesi, P. A. (2025). Cost consequence analysis of natalizumab compared with other high efficacy treatments in patients with relapsing–remitting multiple sclerosis. PharmacoEconomics, 43, 1463–1477. https://doi.org/10.1007/s40273-025-01539-3
Iaffaldano, P., Lucisano, G., Guerra, T., Paolicelli, D., Portaccio, E., Inglese, M., Foschi, M., Patti, F., Granella, F., Romano, S., Cavalla, P., De Luca, G., Gallo, P., Bellantonio, P., Gallo, A., Montepietra, S., Di Sapio, A., Vianello, M., Quatrale, R., . . . Trojano, M. (2024). A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis. Annals of Clinical and Translational Neurology, 11(8), 2008–2015. https://doi.org/10.1002/acn3.52118
Finocchiaro, C., Chisari, C. G., Lo Fermo, S., D’Amico, E., Parrinello, N. L., Romano, A., Palumbo, G. A., Marino, S., Corsale, A. M., Di Raimondo, F., Zappia, M., & Patti, F. (2025). In vivo effects of disease-modifying therapies on immunological subsets in patients with relapsing-remitting multiple sclerosis. Current Neuropharmacology, 23(13), 1783–1796. https://doi.org/10.2174/011570159X360729250319064959
Seferoğlu, M., Tunç, A., Sıvacı, A. Ö., Piri Çınar, B., Destan Bünül, S., Ethemoğlu, Ö., Yalaz Tekan, Ü., & Yetkin, M. F. (2025). Comparative efficacy and safety of extended versus standard interval dosing of natalizumab in relapsing–remitting multiple sclerosis patients: A multicenter analysis. CNS Neuroscience & Therapeutics, 31, e70445. https://doi.org/10.1111/cns.70445
Maersk-Moller, C., Pontieri, L., Stilund, M. L. M., Christensen, J. R., Storr, L. K., Hansen, V., Schäfer, J., Weglewski, A., Quinto Romani, K., Jensen, H. B., Kant, M., Illes, Z., Papp, V., Sejbaek, T., Torring, C. W., Sellebjerg, F., Poulsen, M. B., & Magyari, M. (2025). A national Danish effectiveness study of ocrelizumab versus natalizumab in multiple sclerosis. European Journal of Neurology, 33, e70507. https://doi.org/10.1111/ene.70507
Adamczyk, B., Morawiec, N., Zalejska-Fiolka, J., Kwinta, R., Rakoca, M., Wawrzyniak, S., Sowa, A., Sawa, K., & Adamczyk-Sowa, M. (2025). Evaluation of selected serum adipocytokines in patients with relapsing–remitting multiple sclerosis treated with immunomodulatory second-line drugs. International Journal of Molecular Sciences, 26, 8070. https://doi.org/10.3390/ijms26168070
Chisari, C. G., Aguglia, U., Amato, M. P., Bergamaschi, R., Bertolotto, A., Bonavita, S., Brescia Morra, V., Cavalla, P., Cocco, E., Contel, A., Cottone, S., De Luca, G., Di Sapio, A., Filippi, M., Gallo, A., Gasperini, C., Granella, F., Lus, G., Maimone, D., . . . Patti, F. (2024). Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study. Neurotherapeutics, 21, e00363. https://doi.org/10.1016/j.neurot.2024.e00363
Barbuti, E., Castiello, A., Pozzilli, V., Carotenuto, A., Tomasso, I., Moccia, M., Ruggieri, S., Borriello, G., Lanzillo, R., Brescia Morra, V., Pozzilli, C., & Petracca, M. (2025). Comparative effectiveness, safety and persistence of ocrelizumab versus natalizumab in multiple sclerosis: A real-world, multi-center, propensity score-matched study. Neurotherapeutics, 22, e00537. https://doi.org/10.1016/j.neurot.2025.e00537
Takahashi, K., Nakahara, J., Miura, Y., Ae, R., Nakamichi, K., Harada, M., Mori, K., Sanjo, N., Yukitake, M., Yokote, H., Hamaguchi, T., Yamada, M., & Takao, M. (2025). Natalizumab-associated progressive multifocal leukoencephalopathy after natalizumab extended interval dosing therapy in Japan. Neurology: Neuroimmunology & Neuroinflammation, 12, e200476. https://doi.org/10.1212/NXI.0000000000200476
Gelissen, L. M. Y., van Oosten, B. W., Hogenboom, L., de Jong, B. A., Toorop, A. A., Killestein, J., Strijbis, E. M. M., & van Kempen, Z. L. E. (2025). Wearing-off symptoms persist in the majority of patients with multiple sclerosis after switching from natalizumab to ocrelizumab. Journal of the Neurological Sciences, 479, 125652. https://doi.org/10.1016/j.jns.2025.125652
Nakashima, I., Ohashi, T., Yokoyama, K., Kaida, K., Nakahara, J., Kondo, T., Yoshikura, N., Shimizu, Y., Nohara, C., Sakurai, K., Yokote, H., Niino, M., Yamamura, T., Fujihara, K., Isobe, N., Ochi, H., Mori, M., Kawachi, I., Shimizu, F., . . . Fukazawa, T. (2026). A multicenter, retrospective study in patients with multiple sclerosis treated with natalizumab in a real-world setting in Japan: The REFIND study. Multiple Sclerosis and Related Disorders, 107, 107007. https://doi.org/10.1016/j.msard.2026.107007
Kitsos, D. K., Stavrogianni, K., Dimitriadou, E.-M., Giannopapas, V., Akrivaki, A., Chasiotis, A. K., Roussos, F., Tagaris, G., Tsivgoulis, G., Mastorodemos, V. C., & Giannopoulos, S. (2026). Maternal and neonatal outcomes following natalizumab use during pregnancy in women with multiple sclerosis: A multicenter observational study. Journal of Clinical Neuroscience, 148, 111977. https://doi.org/10.1016/j.jocn.2026.111977
Hellgren, J., Ahlstrom, I., Fornvik Jonsson, M., Compagno Strandberg, M., Hansson, O., Janelidze, S., Svenningsson, A., & Kallen, K. (2025). Comparison of CSF biomarkers in multiple sclerosis patients treated with natalizumab and rituximab. Multiple Sclerosis and Related Disorders, 99, 106479. https://doi.org/10.1016/j.msard.2025.106479
Spelman, T., Simoneau, G., Hyde, R., Kuhelj, R., Alroughani, R., Ozakbas, S., Karabudak, R., Yamout, B. I., Khoury, S. J., Terzi, M., Boz, C., Horakova, D., Kubala Havrdova, E., Weinstock-Guttman, B., Patti, F., Altintas, A., Mrabet, S., Gouider, R., Inshasi, J., . . . Butzkueven, H. (2024). Comparative effectiveness of natalizumab, fingolimod, and injectable therapies in pediatric-onset multiple sclerosis. Neurology, 102, e208114. https://doi.org/10.1212/WNL.0000000000208114
Al-Araji, S., Moccia, M., Jha, A., Zhang, L., Eshaghi, A., Kanber, B., Bianchi, A., Yam, C., Abdel-Mannan, O., Goodkin, O., Pontillo, G., Hamed, W., Mohamud, S., Brownlee, W. J., Chard, D. T., Chataway, J., Chung, K., De Angelis, F., Hammam, A., . . . Ciccarelli, O. (2025). Effectiveness of disease-modifying therapies in patients with late-onset relapsing-remitting multiple sclerosis. Neurology, 105, e213967. https://doi.org/10.1212/WNL.0000000000213967
Khoy, K., Mariotte, D., Defer, G., Petit, G., Toutirais, O., & Le Mauff, B. (2020). Natalizumab in multiple sclerosis treatment: From biological effects to immune monitoring. Frontiers in Immunology, 11, 549842. https://doi.org/10.3389/fimmu.2020.549842
Polman, C. H., O’Connor, P. W., Havrdova, E., et al. (2006). A randomized placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine, 354, 899–910. https://doi.org/10.1056/NEJMoa044397
Stuve, O., & Bennett, J. L. (2007). Pharmacological properties, toxicology, and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases. CNS Drug Reviews, 13(1), 79–95. https://doi.org/10.1111/j.1527-3458.2007.00003.x
Freedman, M. S., Clift, F., Devonshire, V., et al. (2025). First-line use of higher-efficacy disease-modifying therapies in multiple sclerosis: Canadian consensus recommendations. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 1–10. https://doi.org/10.1017/cjn.2025.10342
Ryerson, L. Z., Foley, J., Chang, I., Kister, I., Cutter, G., Metzger, R. R., et al. (2019). Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology, 93(15), e1452–e1462. https://doi.org/10.1212/WNL.0000000000008243
Dobson, R., Dassan, P., Roberts, M., Giovannoni, G., Nelson-Piercy, C., & Brex, P. A. (2019). UK consensus on pregnancy in multiple sclerosis: Association of British Neurologists guidelines. Practical Neurology, 19(2), 106–114. https://doi.org/10.1136/practneurol-2018-002060
Zhovtis Ryerson, L., Frohman, T. C., Foley, J., et al. (2016). Extended interval dosing of natalizumab in multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry, 87, 885–889. https://doi.org/10.1136/jnnp-2015-312940
Bomprezzi, R., & Pawate, S. (2014). Extended interval dosing of natalizumab: A two-center 7-year experience. Therapeutic Advances in Neurological Disorders, 7, 227–231. https://doi.org/10.1177/1756285614540224
Clerico, M., De Mercanti, S. F., Signori, A., et al. (2020). Extending the interval of natalizumab dosing: Is efficacy preserved? Neurotherapeutics, 17(1), 200–207. https://doi.org/10.1007/s13311-019-00776-7
Bloomgren, G., Richman, S., Hotermans, C., et al. (2012). Risk of natalizumab-associated progressive multifocal leukoencephalopathy. New England Journal of Medicine, 366(20), 1870–1880. https://doi.org/10.1056/NEJMoa1107829
Ho, P. R., Koendgen, H., Campbell, N., Haddock, B., Richman, S., & Chang, I. (2017). Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: A retrospective analysis of data from four clinical studies. The Lancet Neurology, 16, 925–933. https://doi.org/10.1016/S1474-4422(17)30282-X
Hellwig, K., Haghikia, A., & Gold, R. (2011). Pregnancy and natalizumab: Results of an observational study in 35 accidental pregnancies during natalizumab treatment. Multiple Sclerosis Journal, 17(8), 958–963. https://doi.org/10.1177/1352458511401944
Wehner, N. G., Shopp, G., Oneda, S., & Clarke, J. (2009). Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an α4 integrin inhibitor. Birth Defects Research Part B: Developmental and Reproductive Toxicology, 86(2), 117–130. https://doi.org/10.1002/bdrb.20190
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Zuzanna Lechowska, Gabriela Piotrowska, Agnieszka Anna Gaczoł, Wiktoria Król, Konrad Kulka, Dominika Jurczak, Julia Koronczok-Matusiak, Zuzanna Kafara, Donata Kowalczyk, Agnieszka Kafara, Rafał Szarek, Katarzyna Michta
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
